Eastern Biotech & Life Sciences, Dubai based company established in Dubiotech Park introducing new Cardiovascular Assessment on the cutting edge of molecular medicine in Middle East Region.
Based on the latest advancements in cardiovascular research, this groundbreaking assessment measures the most important CVD markers available, including crucial new independent factors, a diverse array of lipoproteins, and two computed ratios.
All of these advanced markers play a critical role in assessing the biochemical environment underlying cardiovascular health. This information allows the clinician to accurately address abnormalities relating to heart and vascular diseases.
According to Mr. Pankaj Sohaney-Manager, Middle East "Using this state-of-the-art assessment, you can now better identify individuals who don't show abnormalities in traditional markers of CVD-those who comprise almost 50 percent of all heart attack victims. A clear, color-coded test report will allow you to quickly interpret results, and design a unique, customized nutrition therapy program that can dramatically improve a patient's quality of life, and possibly even save it."
Perhaps the greatest tragedy is that the deleterious consequences of this deadly disease are very often preventable. With advances in medicine, researchers have discovered important early indicators that can significantly change the direction of prophylactic and therapeutic treatment, decreasing the incidence and halting the progression of the disease.
Testing is strongly recommended for patients with the following history or medical conditions:
Family history of cardiovascular disease
Personal history of myocardial infarction, peripheral artery disease, or coronary artery disease
Chronic illness (including chronic fatigue)
Diets high in saturated and trans fats
Use of alcohol,nicotine,drugs (including certain medications)
Use of oral contraceptives
Hormonal imbalances (estradiol, cortisol, insulin, melatonin)
The Comprehensive Cardiovascular Profile 2.0
incorporates the latest breakthroughs in cardiovascular disease research to provide advanced, early warning of CVD risk. This thorough evaluation features an advanced lipid profile with fractionation, independent risk markers (including homocysteine and hs-C-reactive protein), relative risk indices, and Metabolic Syndrome alerts. All of these advanced markers play a critical role in the biochemical environment underlying cardiovascular health. The insight they provide allows the clinician to accurately address abnormalities relating to heart and vascular diseases.
A clear, color-coded test report allows the clinician to quickly interpret results and design a novel, custom-tailored prevention program that can dramatically improve a patient's quality of life, and possibly even save it. The kit is developed by Genova Diagnostics and in Middle East it is available and promoted through Eastern Biotech Life Sciences FZ-LLC.